嗎啡藥物市場規模 - 按劑型（注射、口服）、應用（疼痛管理 [癌症、神經性、骨關節炎]、安寧療護、止瀉藥、感冒和咳嗽、麻醉）、配銷通路、最終用途和預測，2024年 - 2032

2024年至2032年，全球嗎啡藥物市場複合年成長率將超過6.5%。隨著安寧療護服務在全球擴展，嗎啡成為管理臨終疼痛和提高病患生活品質的基石。它在減輕劇烈疼痛方面的功效使其成為為末期病人提供舒適和緩解所不可或缺的。對安寧療護的日益重視凸顯了疼痛管理在醫療保健中的重要性。它增加了對嗎啡等易於使用且有效的鴉片類藥物的需求，確保全球患者獲得有尊嚴和富有同情心的臨終關懷。

市場競爭格局的特點是幾家主要的嗎啡藥品生產商專注於藥品生產和分銷。普渡製藥 (Purdue Pharma)、強生 (Johnson & Johnson) 和 Mallinckrodt Pharmaceuticals 等公司憑藉其廣泛的產品組合和全球市場覆蓋率在市場上佔據主導地位。這些製造商根據產品效率、法規遵守情況、安全性和藥物傳輸技術的發展進行競爭，以滿足醫療保健供應商和患者需要疼痛管理解決方案的需求。

整個嗎啡藥物市場根據劑型、配銷通路、應用、最終用途和地區進行分類。

到 2032 年，口腔領域的複合年成長率將出現顯著的成長。此外，全球慢性疼痛的盛行率不斷上升，也刺激了口服嗎啡製劑的處方率提高。此外，醫療保健提供者對口服嗎啡在平衡疼痛緩解和患者安全方面的好處的認知不斷提高，促使其在臨床實踐中得到越來越多的採用，從而增加了口服藥物領域的需求。

到 2032 年，安寧療護領域將在嗎啡藥物市場佔據重要佔有率，因為它在治療與末期疾病相關的嚴重疼痛方面發揮著至關重要的作用。隨著安寧療護在改善末期疾病的生活品質方面獲得認可，嗎啡在減輕疼痛和增強舒適度方面的功效已變得不可或缺。醫療保健提供者越來越依賴嗎啡來減輕身體痛苦，以確保有尊嚴的臨終關懷。不斷發展的醫療政策和指南強化了這一趨勢，這些政策和指南優先考慮將疼痛管理作為整體患者護理的一個組成部分，從而推動了安寧療護中對嗎啡的需求。

到 2032 年，亞太地區嗎啡藥物市場的複合年成長率將保持樂觀。此外，亞太地區醫療基礎設施的改善和醫療支出的增加正在促進更多人獲得止痛藥。隨著該地區對安寧療護的認知不斷提高，人們擴大接受和採用嗎啡作為管理臨終疼痛和改善患者舒適度的重要組成部分，從而增加了其需求。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 慢性疼痛的盛行率不斷增加
    • 安寧療護意識不斷增強
    • 藥物製劑技術進步
    • 外科手術數量不斷增加
  • 產業陷阱與挑戰
    • 不良反應和過量的風險
    • 對鴉片類藥物成癮和濫用的擔憂
• 成長潛力分析
• 監管環境
• 管道分析
• 波特的分析
• PESTEL分析
• 未來市場趨勢

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按劑型，2021 - 2032

• 主要趨勢
• 可注射
• 口服
• 其他劑型

第 6 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 疼痛管理
  • 癌症痛
  • 神經性疼痛
  • 骨關節炎疼痛
  • 其他疼痛管理
• 安寧療護
• 止瀉藥
• 麻醉
• 感冒止咳藥
• 其他應用

第 7 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥房
• 網路藥房

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 醫院和診所
• 門診手術中心
• 其他最終用戶

第 9 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 10 章：公司簡介

• Alcaliber S.A.
• Daiichi Sankyo Company Limited
• Hikma Pharmaceuticals PLC
• Mallinckrodt plc
• Pfizer Inc.
• Purdue Pharma L.P.
• Sandoz AG
• Taj Pharmaceuticals Limited
• Verve Health Care Ltd.
• Viatris Inc.

Global Morphine Drugs Market will witness over 6.5% CAGR from 2024 to 2032. Morphine's pivotal role in palliative care significantly spurs the demand. As palliative care services expand globally, morphine emerges as a cornerstone in managing end-of-life pain and enhancing patients' quality of life. Its efficacy in alleviating severe pain makes it indispensable in providing comfort and relief for terminally ill individuals. This growing emphasis on palliative care highlights the importance of pain management in healthcare. It amplifies the need for accessible and effective opioid medications like morphine, ensuring dignified and compassionate end-of-life care for patients globally.

The competitive landscape in the market is characterized by several key morphine drug producers focusing on pharmaceutical production and distribution. Companies such as Purdue Pharma, Johnson & Johnson, and Mallinckrodt Pharmaceuticals dominate the market with their extensive product portfolios and global market reach. These manufacturers compete based on product efficiency, regulatory adherence, safety profiles, and developments in drug delivery technologies to meet the demands of healthcare vendors and patients requiring pain management solutions.

The overall morphine drugs market is classified based on dosage form, distribution channel, application, end-use, and region.

The oral segment will experience prominent CAGR expansion through 2032. Advancements in oral drug delivery technology have enhanced the efficacy and convenience of administering morphine, making it more accessible for patients requiring long-term pain management. Additionally, the increasing prevalence of chronic pain conditions globally has spurred greater prescription rates for oral morphine formulations. Moreover, heightened awareness among healthcare providers about the benefits of oral morphine in balancing pain relief and patient safety has contributed to its growing adoption in clinical practice, escalating its demand in the oral drug segment.

The palliative care segment will garner a significant morphine drugs market share by 2032, owing to its crucial role in managing severe pain associated with terminal illnesses. As palliative care gains recognition for improving the quality of life in end-stage diseases, morphine's effectiveness in alleviating pain and enhancing comfort has become indispensable. Healthcare providers increasingly rely on morphine to ensure dignified end-of-life care by providing relief from physical suffering. This trend is reinforced by evolving healthcare policies and guidelines that prioritize pain management as an integral component of holistic patient care, driving the demand for morphine in palliative settings.

The CAGR for the Asia Pacific morphine drugs market will be optimistic through 2032. Increasing incidences of chronic diseases and cancer-related pain are ushering in the need for effective pain management solutions like morphine. Moreover, improvements in healthcare infrastructure and rising healthcare expenditures in the Asia Pacific are facilitating greater access to pain relief medications. As awareness about palliative care increases in the region, there is a growing acceptance and adoption of morphine as a crucial component in managing end-of-life pain and improving patient comfort, boosting its demand.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic pain conditions
    • 3.2.1.2 Growing awareness of palliative care
    • 3.2.1.3 Technological advancements in drug formulations
    • 3.2.1.4 Rising number of surgical procedures
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Risk of adverse effects and overdose
    • 3.2.2.2 Concerns about opioid addiction and abuse
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Injectable
• 5.3 Oral
• 5.4 Other dosage forms

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Pain management
  • 6.2.1 Cancer pain
  • 6.2.2 Neuropathic pain
  • 6.2.3 Osteoarthritis pain
  • 6.2.4 Other pain managements
• 6.3 Palliative care
• 6.4 Diarrhea suppressant
• 6.5 Anesthesia
• 6.6 Cold & cough suppressant
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Ambulatory surgical centers
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Alcaliber S.A.
• 10.2 Daiichi Sankyo Company Limited
• 10.3 Hikma Pharmaceuticals PLC
• 10.4 Mallinckrodt plc
• 10.5 Pfizer Inc.
• 10.6 Purdue Pharma L.P.
• 10.7 Sandoz AG
• 10.8 Taj Pharmaceuticals Limited
• 10.9 Verve Health Care Ltd.
• 10.10 Viatris Inc.